{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:08:09Z","timestamp":1794665289762,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13782-w","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:23:56Z","timestamp":1781259836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adverse events associated with candida infections in secukinumab treatment"],"prefix":"10.1186","volume":"26","author":[{"given":"Chongli","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"2\u20133","key":"13782_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12026-011-8226-x","volume":"50","author":"SL Gaffen","year":"2011","unstructured":"Gaffen SL, Hern\u00e1ndez-Santos N, Peterson AC. IL-17 signaling in host defense against Candida albicans. Immunol Res. 2011;50(2\u20133):181\u20137.","journal-title":"Immunol Res"},{"issue":"1","key":"13782_CR2","doi-asserted-by":"publisher","first-page":"e0037822","DOI":"10.1128\/iai.00378-22","volume":"91","author":"J Tang","year":"2023","unstructured":"Tang J, et al. The Protective Role of Interleukin 17A in Acinetobacter baumannii Pneumonia Is Associated with Candida albicans in the Airway. Infect Immun. 2023;91(1):e0037822.","journal-title":"Infect Immun"},{"issue":"3","key":"13782_CR3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/bjd.14965","volume":"176","author":"K Reich","year":"2017","unstructured":"Reich K, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;176(3):752\u20138.","journal-title":"Br J Dermatol"},{"key":"13782_CR4","doi-asserted-by":"publisher","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","volume":"102","author":"AB Gottlieb","year":"2022","unstructured":"Gottlieb AB, et al. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. Acta Derm Venereol. 2022;102:adv00698.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"13782_CR5","first-page":"34","volume":"22","author":"L Mastorino","year":"2024","unstructured":"Mastorino L, et al. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. J Dtsch Dermatol Ges. 2024;22(1):34\u201342.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"13782_CR6","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","volume":"144","author":"JG Krueger","year":"2019","unstructured":"Krueger JG, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144(3):750\u201363.","journal-title":"J Allergy Clin Immunol"},{"key":"13782_CR7","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu Y, et al. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System. Front Pharmacol. 2022;13:862508.","journal-title":"Front Pharmacol"},{"issue":"2","key":"13782_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/rheumatology\/keac358","volume":"62","author":"B Glintborg","year":"2023","unstructured":"Glintborg B, et al. Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries. Rheumatology (Oxford). 2023;62(2):647\u201358.","journal-title":"Rheumatology (Oxford)"},{"key":"13782_CR9","doi-asserted-by":"publisher","first-page":"p2442603","DOI":"10.1155\/2022\/2442603","volume":"2022","author":"Y Feng","year":"2022","unstructured":"Feng Y, et al. Risk of Candida Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int J Clin Pract. 2022;2022:p2442603.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"13782_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"13782_CR11","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","volume":"3","author":"PM Cutroneo","year":"2023","unstructured":"Cutroneo PM, et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul. 2023;3:1323057.","journal-title":"Front Drug Saf Regul"},{"issue":"3","key":"13782_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","volume":"19","author":"S Cecco","year":"2024","unstructured":"Cecco S, et al. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System. Target Oncol. 2024;19(3):435\u201345.","journal-title":"Target Oncol"},{"issue":"4","key":"13782_CR13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/cmi.2015.105","volume":"13","author":"X Song","year":"2016","unstructured":"Song X, et al. The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity. Cell Mol Immunol. 2016;13(4):418\u201331.","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"13782_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/mi.2014.57","volume":"8","author":"K Trautwein-Weidner","year":"2015","unstructured":"Trautwein-Weidner K, et al. IL-17-mediated antifungal defense in the oral mucosa is independent of neutrophils. Mucosal Immunol. 2015;8(2):221\u201331.","journal-title":"Mucosal Immunol"},{"issue":"8","key":"13782_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.4049\/jimmunol.2400510","volume":"213","author":"L Dos Santos Dias","year":"2024","unstructured":"Dos Santos Dias L, Lionakis MS. IL-17: A Critical Cytokine for Defense against Oral Candidiasis. J Immunol. 2024;213(8):1049\u201351.","journal-title":"J Immunol"},{"key":"13782_CR16","doi-asserted-by":"crossref","unstructured":"Mengesha BG, Conti HR. The Role of IL-17 in Protection against Mucosal Candida Infections. J Fungi (Basel), 2017. 3(4).","DOI":"10.3390\/jof3040052"},{"issue":"2","key":"13782_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20081463","volume":"206","author":"HR Conti","year":"2009","unstructured":"Conti HR, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 2009;206(2):299\u2013311.","journal-title":"J Exp Med"},{"issue":"4","key":"13782_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/ar3893","volume":"14","author":"AR Huppler","year":"2012","unstructured":"Huppler AR, Bishu S, Gaffen SL. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther. 2012;14(4):217.","journal-title":"Arthritis Res Ther"},{"key":"13782_CR19","doi-asserted-by":"publisher","first-page":"100266","DOI":"10.1016\/j.lanepe.2021.100266","volume":"13","author":"L Davidson","year":"2022","unstructured":"Davidson L, et al. Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources. Lancet Reg Health Eur. 2022;13:100266.","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"13782_CR20","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/ced\/llae400","volume":"50","author":"M Megna","year":"2025","unstructured":"Megna M, et al. The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience - IL PSO (Italian Landscape Psoriasis). Clin Exp Dermatol. 2025;50(4):858\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"13782_CR21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","volume":"89","author":"KA Papp","year":"2023","unstructured":"Papp KA, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. J Am Acad Dermatol. 2023;89(6):1149\u201358.","journal-title":"J Am Acad Dermatol"},{"key":"13782_CR22","doi-asserted-by":"publisher","first-page":"1372693","DOI":"10.3389\/fimmu.2024.1372693","volume":"15","author":"S Khan","year":"2024","unstructured":"Khan S, et al. Interleukin inhibitors and the associated risk of candidiasis. Front Immunol. 2024;15:1372693.","journal-title":"Front Immunol"},{"issue":"2","key":"13782_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.5021\/ad.20.327","volume":"35","author":"JI Seo","year":"2023","unstructured":"Seo JI, Shin MK, Jeong KH. Recurrent Esophageal Candidiasis Induced by Secukinumab: Discrepancy between Clinical Trials and Real-World Data. Ann Dermatol. 2023;35(2):158\u201360.","journal-title":"Ann Dermatol"},{"issue":"3","key":"13782_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-024-01122-2","volume":"14","author":"R Sun","year":"2024","unstructured":"Sun R, et al. Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials. Dermatol Ther (Heidelb). 2024;14(3):729\u201343.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"13782_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s13555-022-00687-0","volume":"12","author":"AW Armstrong","year":"2022","unstructured":"Armstrong AW, et al. A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. Dermatol Ther (Heidelb). 2022;12(3):787\u2013800.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"13782_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jaad.2024.02.045","volume":"91","author":"NC Bahr","year":"2024","unstructured":"Bahr NC, et al. Low incidence of invasive fungal infections in a large observational cohort of patients initiating IL-17 or IL-23 inhibitor therapy, United States, 2016\u20132022. J Am Acad Dermatol. 2024;91(1):119\u201322.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"13782_CR27","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40257-023-00782-8","volume":"24","author":"M Sticherling","year":"2023","unstructured":"Sticherling M, et al. Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials. Am J Clin Dermatol. 2023;24(5):821\u201335.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"13782_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.","journal-title":"Arthritis Res Ther"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13782-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13782-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13782-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:02:35Z","timestamp":1787230955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13782-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13782"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13782-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used only publicly available, de-identified data from the U.S. FDA Adverse Event Reporting System (FAERS) and involved no direct interaction with human participants or access to identifiable private information. All analyses were conducted in accordance with the principles of the Declaration of Helsinki (2013; Fortaleza, Brazil).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No patient recruitment or direct human participation was involved.","order":2,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study contains no individual person-level identifiable data, images, or media requiring publication consent.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1534"}}